Inovio Pharmaceuticals has reported that its Pennvax-GP HIV vaccine combination has succeeded in an early stage clinical trial by evoking nearly 100% immune response rates in participants.
Shire’s swelling disorder treatment, lanadelumab, has met its primary endpoint and all secondary endpoints in a phase 3 study.
ImmunoGen has reported promising safety and efficacy data from monotherapy and combination trials with mirvetuximab soravtansine in patients with folate receptor alpha (FRα)-positive epithelial ovarian cancer (EOC).
Ardelyx reported positive, topline results from the T3MPO-1 trial, the first of two Phase 3 trials evaluating tenapanor for the treatment of patients with irritable bowel syndrome with constipation (IBS-C).
Eli Lilly's galcanezumab has met its primary endpoint in three phase 3 studies (EVOLVE-1, EVOLVE-2 and REGAIN) showing statistically significant reductions in the number of monthly migraine headache days against placebo at both studied doses.
Roche’s phase III IMvigor211 study of Tecentriq (atezolizumab) in people with locally advanced or metastatic urothelial cancer (mUC) whose disease progressed during or after treatment with a platinum-based chemotherapy (previously treated) has failed to meet its primary endpoint of overall survival (OS) compared to chemotherapy.
Daiichi Sankyo announced the initiation of the ENVISAGE-TAVI AF study of Lixiana by enrolling the first patient in the trial.
Myovant Sciences has reported positive results from a placebo-controlled Phase 2 dose-finding trial evaluating the ability of relugolix to decrease heavy menstrual bleeding in women with uterine fibroids which was conducted by Takeda Pharmaceutical in Japan.
GlaxoSmithKline and Innoviva said that their asthma drug Relvar Ellipta yielded positive results from the Salford Lung Study (SLS) in 4,233 asthma patients treated by their own general practitioner in everyday clinical practice.
Teva Pharmaceutical Industries and Active Biotech announced that CONCERTO trial for laquinimod in patients with relapsing-remitting multiple sclerosis (RRMS) failed to meet its primary endpoint.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.